Related Experiment Video

Updated: Jul 7, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

S E Rosenbaum1, S Wu, M A Newman

  • 1Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N. St. Clair St., Suite 1600, Chicago, IL 60611, USA.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|February 16, 2008
PubMed
Abstract

Insights

Sunitinib, a multikinase inhibitor, effectively treats cancers but frequently causes skin issues. Managing these dermatological side effects is crucial for patient quality of life and treatment adherence.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Sunitinib is a multikinase inhibitor used for renal cell carcinoma and gastrointestinal stromal tumors.
  • While effective, sunitinib frequently causes dermatological adverse reactions.
  • These skin toxicities can negatively impact patient quality of life and treatment adherence.

Purpose of the Study:

  • To review and summarize the incidence and types of dermatological adverse reactions associated with sunitinib.
  • To highlight the need for evidence-based recommendations for managing these side effects.

Main Methods:

  • Information was gathered from Pfizer Medical Information and major oncology conference abstracts (2007).
  • A comprehensive literature search was conducted using MEDLINE, Cochrane Library, and EMBASE databases.
  • Data was accessed up to June 30, 2007.

Main Results:

  • Hand-foot skin reaction occurred in 19% of patients (5% grade 3-4).
  • Skin discoloration (28%), dry skin (16%), and skin rash (13%) were also common.
  • Other reactions included dermatitis (8%), hair color changes (10%), alopecia (6%), and phototoxicity (<0.1%).

Conclusions:

  • Dermatological reactions are a frequent occurrence with sunitinib treatment.
  • Effective management strategies are necessary to improve patient outcomes and quality of life.
  • Further research is needed to develop evidence-based treatment guidelines for sunitinib-induced dermatological toxicities.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: